U.S. Pharma Stock News

NasdaqGS:HAS
NasdaqGS:HASLeisure

Hasbro’s New Debt Deal To Fund Digital IP Might Change The Case For Investing In Hasbro (HAS)

Hasbro, Inc. recently completed a US$399.4 million offering of 4.650% senior unsecured notes due March 12, 2031, to refinance older debt and support its shift toward a digital-first, intellectual property-focused business model. This combination of strong earnings led by Magic: The Gathering and proactive balance sheet management highlights how Hasbro is reshaping itself around higher-margin gaming and entertainment assets. We’ll now examine how Hasbro’s debt refinancing to support its...
NYSE:HUBB
NYSE:HUBBElectrical

Is Hubbell (HUBB) Pricing Look Stretched After Strong Multi Year Share Gains?

Wondering if Hubbell at around US$477.97 is priced for perfection or still leaves room on the table? This article walks through the numbers so you can judge whether the current tag feels stretched or reasonable. The stock has seen a 2.6% decline over the past week and a 5.6% decline over the last 30 days, while still sitting on a 44.6% 1 year return and a 172.8% return over 5 years. That mix of recent pullback and longer term strength raises fair questions about where value stands...
NYSE:HOG
NYSE:HOGAuto

Harley-Davidson Insider Buying Sparks Fresh Look At Value And Risks

Harley-Davidson CEO and a company director recently purchased additional NYSE:HOG shares. Director Lori Flees made a sizeable insider purchase, increasing her personal stake in the company. These transactions add a fresh data point on insider sentiment at a time when the share price is around $18.2. For investors watching Harley-Davidson, the insider buying comes after a tough stretch for NYSE:HOG, with the stock down 6.5% over the past week and 9.6% over the past month. Returns are also...
NasdaqGS:CHRW
NasdaqGS:CHRWLogistics

C.H. Robinson’s 100 Trillion Data Points Reframe Its AI Advantage

C.H. Robinson Worldwide (NasdaqGS:CHRW) has publicly detailed the scale of its proprietary logistics dataset, which now feeds over 100 trillion real world data points into its Lean AI system. The expanded AI platform coordinates hundreds of AI agents that support millions of shipping decisions across global freight and logistics operations. The company reports measurable benefits for customers, including faster time to market and more consistent pickup performance. C.H. Robinson is putting...
NYSE:CPNG
NYSE:CPNGMultiline Retail

Is It Time To Revisit Coupang (CPNG) After Recent Share Price Weakness

If you are looking at Coupang and wondering whether the current share price reflects its true worth, you are not alone. Many investors are asking the same question. Coupang's share price closed at US$18.77 most recently, with returns of a 1.7% decline over the last 7 days, a 1.2% gain over 30 days, a 19.7% decline year to date and a 15.7% decline over 1 year, while the 3 year return sits at 45.4% and the 5 year return at a 56.6% decline. Recent coverage around Coupang has focused on its...
NasdaqGS:CAPR
NasdaqGS:CAPRBiotechs

Is It Too Late To Consider Capricor Therapeutics (CAPR) After Strong Multi Year Share Gains?

Wondering whether Capricor Therapeutics at around US$33.57 is still offering value or has already priced in the story? This article will walk you through what the numbers are actually saying about the stock. The share price has been volatile, with returns of 31.6% over the past week, 33.3% over the past month, 18.6% year to date, and 156.8% over the last year, alongside a very large 3 year gain and a more than 5x gain over 5 years. Recent interest in Capricor Therapeutics has been shaped by...
NYSE:GME
NYSE:GMESpecialty Retail

Is GameStop (GME) Pricing Reflect The Turnaround Story Or Meme Stock Sentiment

This article focuses on giving you a clear framework to assess whether GameStop's current share price aligns with its underlying value, or whether the story is driven more by sentiment. Over the last 7 days GameStop has returned 2.5%, with a 30 day return of a 0.7% decline, a year to date return of 18.6%, a 1 year return of 12.5%, a 3 year return of 55.2%, and a 5 year return of a 52.8% decline. This highlights how mixed the stock's recent history has been. These moves sit against a backdrop...
NYSE:AWR
NYSE:AWRWater Utilities

Is American States Water’s (AWR) Bigger 2026 Capex Plan Quietly Redefining Its Core Earnings Story?

In February 2026, American States Water reported fourth-quarter 2025 diluted earnings per share of US$0.74 and outlined plans to invest US$185 million to US$225 million in capital expenditures during 2026, with adjusted results showing improvement in its core water business versus the prior year. This combination of stronger underlying water segment earnings and a sizeable 2026 investment program highlights management’s focus on reinforcing long-term infrastructure and operational...
NYSE:SILA
NYSE:SILAHealth Care REITs

A Look At Sila Realty Trust (SILA) Valuation After Truist Reaffirms Positive Outlook

Recent trading in Sila Realty Trust (SILA) has been influenced by Truist Securities maintaining a positive view after the latest quarterly update, where earnings per share missed expectations but revenue came in slightly ahead of forecasts. See our latest analysis for Sila Realty Trust. At a share price of US$25.03, Sila Realty Trust has seen a 1-day share price return of 1.38% and a 90-day share price return of 11.05%. Its 1-year total shareholder return of 5.07% and 3-year total shareholder...
NYSE:MOS
NYSE:MOSChemicals

Mosaic Turns Fertilizer Byproduct Into Rare Earths Opportunity In Brazil

Mosaic (NYSE:MOS) has entered a joint agreement with Rainbow Rare Earths to advance the Uberaba rare earths project in Brazil. The partners plan to process phosphogypsum, a fertilizer byproduct, to produce rare earths such as neodymium and praseodymium. The initiative expands Mosaic’s business focus beyond fertilizers into materials used in clean energy and high tech applications. Mosaic, trading at $29.15, is better known for its fertilizers, so this rare earths move gives investors a...
NasdaqCM:CLDX
NasdaqCM:CLDXBiotechs

Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria

Celldex Therapeutics recently presented new and additional positive Phase 2 and open-label extension data on its antibody barzolvolimab in chronic inducible urticaria subtypes at the 2026 AAAAI Annual Meeting, showing rapid improvements in urticaria control on both initial and repeat treatment. A key insight from these results is that many patients who initially achieved complete response in cold urticaria or symptomatic dermographism regained similar disease control after retreatment,...
NYSE:TROX
NYSE:TROXChemicals

Assessing Tronox Holdings (TROX) Valuation After Recent Share Price Volatility And Mixed Fair Value Signals

Event overview and recent price context Tronox Holdings (TROX) has drawn attention after recent share price volatility, with the stock down about 10% over the past month but up roughly 43% in the past 3 months. For investors, that mix of short term weakness and stronger recent momentum raises questions about how the current US$6.76 share price lines up with Tronox Holdings' value score of 4 and its reported financial profile. See our latest analysis for Tronox Holdings. Looking beyond the...
NYSE:IBM
NYSE:IBMIT

Has IBM (IBM) Cooled Share Price Create A Fresh Valuation Opportunity Today

If you are wondering whether International Business Machines (IBM) still offers value at around US$248.87 per share, you are not alone. This article will help you frame that question clearly. The stock has slipped about 0.5% over the last week and 16.0% over the last month, while still showing a 2.2% return over 1 year and a very large gain over 3 and 5 years. Recent headlines have focused on IBM's positioning as a major software and services player, with investors reassessing how its mix of...
NYSE:VVV
NYSE:VVVSpecialty Retail

Valvoline Blends Community Giving And Finance Shakeup In Evolving Investor Story

Valvoline (NYSE:VVV) has launched the Happy to Help Fund in partnership with Blue Grass Community Foundation to back mental and physical well-being projects for children and youth in Lexington. The company has named Jordan M. Denny as Chief Accounting Officer and Controller, marking a key update to its executive leadership team. For you as an investor, this pairs a fresh community initiative with a leadership change at a company best known for vehicle lubricants, services, and related...
NYSE:SGHC
NYSE:SGHCHospitality

Is Super Group (SGHC) Using Rising Dividends to Recast Its Capital Return Narrative?

Super Group (SGHC) recently reported its Q4 results, highlighting record customer numbers, rising deposits, the completion of a major African tech migration, and the launch of its ZAR Supercoin in South Africa. The company also returned US$156 million to shareholders and raised its quarterly dividend target, underlining a stronger focus on capital returns alongside product innovation. Next, we’ll examine how the Q4 earnings update and increased dividend plans could influence Super Group’s...
NasdaqGS:CRNX
NasdaqGS:CRNXPharmaceuticals

Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility

Recent share performance and business snapshot Crinetics Pharmaceuticals (CRNX) has drawn investor attention after a weak month for the share price, with the stock showing negative returns over the past month and past 3 months despite a positive 1 year total return. The clinical stage company focuses on rare endocrine diseases, with its lead candidate Paltusotine in Phase 3 trials and several earlier stage programs. This context may influence how investors weigh recent share price moves...
NasdaqGS:COKE
NasdaqGS:COKEBeverage

How Investors Are Reacting To Coca-Cola Consolidated (COKE) Hitting Record Highs After 16-Year Revenue Streak

In recent days, Coca-Cola Consolidated, the largest Coca-Cola bottler in the US, reached new all-time stock highs following 16 consecutive years of positive revenue growth. This performance highlights how a steady, low-beta bottling business serving 60 million consumers across 14 states can attract considerable investor attention. We’ll now examine how Coca-Cola Consolidated’s 16-year revenue growth streak shapes its investment narrative for current and prospective shareholders. Capitalize...
NasdaqCM:IMUX
NasdaqCM:IMUXBiotechs

A Look At Immunic (IMUX) Valuation As Reverse Split Proposal And Conference Appearance Draw Attention

Immunic (IMUX) is back on investors’ radar after proposing a reverse stock split ahead of an April 14 special shareholder meeting, while management prepares to speak at the Leerink Global Healthcare Conference on March 11. See our latest analysis for Immunic. Those recent corporate updates have come alongside sharp share price moves, with a 1 day share price return of 12.4% and a 30 day share price return of 103.08% contributing to a year to date share price return of 148.71%. However, the 5...
NYSE:TXT
NYSE:TXTAerospace & Defense

Is Textron (TXT) Now Attractively Priced After Recent Share Price Pullback?

If you are wondering whether Textron's current share price lines up with its underlying worth, this article will walk you through what the numbers are saying and where valuation questions remain. Textron closed at US$93.27, with returns of a 6.1% decline over 7 days, a 2.3% decline over 30 days, 7.1% year to date, 28.4% over 1 year, 41.4% over 3 years, and 69.1% over 5 years. Together, these figures provide context for judging today's price tag. Recent news coverage has focused on Textron's...
NYSE:PACS
NYSE:PACSHealthcare

Does PACS Group’s (PACS) Optum CEO Board Addition Reframe Its Value-Based Care Ambitions?

In early March 2026, PACS Group, Inc. appointed Patrick H. Conway, MD, MSc, the CEO of Optum and former senior CMS leader, to its Board of Directors, adding a rare mix of clinical, regulatory, and large-scale health system leadership to its governance. This move brings to PACS Group a director who helped design major U.S. value-based payment models and still practices medicine, potentially sharpening the company’s focus on quality and reimbursement innovation in post-acute and skilled...
NasdaqGS:AEIS
NasdaqGS:AEISElectronic

Is It Too Late To Consider Advanced Energy Industries (AEIS) After A 198% One Year Surge?

If you are looking at Advanced Energy Industries and wondering whether the current share price really stacks up, you are not alone. This article will walk through what that price might imply about value. The stock recently closed at US$314.84, with returns of 12.8% over 30 days, 41.8% year to date and 198.4% over the past year, which can change how investors think about both upside and risk. These moves sit against a backdrop of ongoing interest in power conversion and control solutions, as...
NasdaqGS:OUST
NasdaqGS:OUSTElectronic

Ouster (OUST) Is Up 10.6% After First Quarterly Profit, Stereolabs Deal And Stock Shelf Filing – Has The Bull Case Changed?

In early March 2026, Ouster, Inc. reported its fourth-quarter and full-year 2025 results, delivering US$62.18 million in quarterly revenue and US$3.99 million in net income, and issued first-quarter 2026 revenue guidance of US$45 million to US$48 million while filing an US$84.43 million shelf registration for common stock tied to an ESOP offering. Alongside its first profitable quarter and the acquisition of Stereolabs to broaden its sensor technology beyond lidar, Ouster also saw insider...
NasdaqGS:MGNI
NasdaqGS:MGNIMedia

Is There Now An Opportunity In Magnite (MGNI) After Mixed Multi‑Year Share Returns?

If you are wondering whether Magnite's current share price lines up with its underlying value, you are not alone. This article focuses on what the numbers actually say about the stock. The share price closed at US$13.03, with returns of 11.7% over 30 days, a 5.8% decline over 7 days, a nearly flat 0.1% decline over 1 year, a 55.1% gain over 3 years, and a 73.4% decline over 5 years. Recent coverage around Magnite has centered on its role in the ad tech space and how investors are thinking...
NasdaqGM:VNDA
NasdaqGM:VNDABiotechs

Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid

Vanda Pharmaceuticals recently received a decision from the U.S. FDA granting a rare formal evidentiary public hearing to review the agency’s proposed refusal to approve a supplemental new drug application for HETLIOZ (tasimelteon) as a treatment for jet lag disorder. This hearing, which follows Vanda’s earlier legal win requiring the FDA to more fully address its clinical evidence, highlights unusually high regulatory and scientific scrutiny around expanding HETLIOZ into a large, currently...